Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness - Heard on the Street — WSJ
By David WainerThere is a strange paradox haunting healthcare investing right now.Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.The past few months drove this home, with billions in market value vanishing. Nov…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.